The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi ...

Early CDMO engagement can be valuable, particularly when it helps development teams understand technical requirements, ...

A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reaction, ...

U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease ...

Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug ...

Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...

In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein ...

The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a ...

Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s ...

Roche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a ...

City Therapeutics, a buzzy biotechnology startup working on new types of RNA interference therapies, secured $200 million in ...

The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an ...